文献速递自身免疫性与大疱性皮肤病

寻常型与落叶型天疱疮患者抗桥粒胶蛋白3抗体的患病率及致病性

Prevalence and pathogenic activity of anti-desmocollin-3 antibodies in patients with pemphigus vulgaris and pemphigus foliaceus.
PubMed 文献 · Br J Dermatol · 2025-01-01

该研究用新型ALBIA法检测146例天疱疮患者血清中抗DSC3胞外域和胞内域IgG/IgA抗体,发现21.2%患者阳性,且抗胞内域DSC3抗体在抗DSG1-3谱与临床不符者中占44%;体外和小鼠实验证实抗胞内域DSC3抗体具有致病性,可加剧水疱形成。

要点

  • 天疱疮患者中抗DSC3抗体阳性率21.2%,以IgA为主。
  • 抗胞内域DSC3抗体见于44%抗DSG1-3谱与临床不符的患者。
  • 抗胞内域DSC3抗体在体外和小鼠中均显示致病性。

核心结论

  • 抗胞内域DSC3抗体具有致病性,可解释部分天疱疮患者临床表型与抗DSG1-3抗体谱不一致的现象。

研究设计与样本

  • 研究纳入146例天疱疮患者,采用新型可寻址激光珠免疫分析(ALBIA)检测抗DSC3胞外域和胞内域IgG/IgA抗体。
  • 通过角质形成细胞解离实验、重组胞内域DSC3免疫小鼠及被动转移抗胞内域DSC3单克隆抗体至新生小鼠进行致病性测试。

主要发现

  • 天疱疮患者血清中抗胞外域DSC3或抗胞内域DSC3 IgG和/或IgA抗体检出率为21.2%,健康供者分别为4.0%(P < 0.001)和5.0%(P < 0.001)。
  • 大多数抗DSC3抗体为IgA。
  • 在血清抗DSG1-3抗体谱与临床和组织学特征不符(按补偿理论)的天疱疮患者中,44%检测到抗胞内域DSC3抗体。
  • 抗胞内域DSC3 IgG和IgA抗体在体外诱导角质形成细胞单层解离,用重组胞内域DSC3预吸附后该作用被消除;免疫小鼠的IgG在体外诱导棘层松解。
  • 在新生小鼠中,被动转移抗胞内域DSC3单克隆抗体联合抗DSG1-3抗体加剧水疱形成。

关键数值与推荐

  • 抗胞外域DSC3或抗胞内域DSC3 IgG和/或IgA抗体在天疱疮患者中检出率为21.2%,健康供者分别为4.0%(P < 0.001)和5.0%(P < 0.001)。
  • 抗胞内域DSC3抗体在抗DSG1-3谱与临床不符的天疱疮患者中检出率为44%。

临床怎么用

  • 对于临床表型与抗DSG1-3抗体谱不一致的天疱疮患者,可考虑检测抗胞内域DSC3抗体以辅助解释病情。
  • ALBIA法可用于检测抗DSC3抗体,但需进一步验证其常规临床应用价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Desmocollin-3 (DSC3) is a calcium-dependent desmosomal cadherin that plays an essential role in cell-cell adhesion. IgG antibodies (Abs) directed against the extracellular (EC) domain of DSC3 have occasionally been detected in rare types of pemphigus. Investigations into the prevalence of anti-EC-DSC3 IgG Abs and those targeting the intracellular (IC) domain of DSC3 in pemphigus vulgaris and pemphigus foliaceus sera, and their potential pathogenic activity, have yielded conflicting results. OBJECTIVES: To assess the prevalence and pathogenicity of Abs directed against the EC and IC domains of DSC3 in patients with pemphigus. METHODS: Anti-DSC3 IgG and IgA directed against the EC and IC domains of DSC3 were assayed in 146 patients with pemphigus using a newly developed addressable laser bead immunoassay. The pathogenicity of these autoAbs was first tested in vitro using a keratinocyte dissociation assay with patients' sera or from C57BL/6 mice immunized with recombinant IC-DSC3. In vivo pathogenicity was tested by passive transfer of an anti-IC-DSC3 monoclonal Ab (mAb) derived from a hybridoma (A9) into neonatal mice. RESULTS: Anti-EC-DSC3 or anti-IC-DSC3 IgG and/or IgA Abs were detected in 21.2% of sera from patients with pemphigus vs. 4.0% (P < 0.001) and 5.0% (P < 0.001) of sera from healthy donors, respectively. Most anti-DSC3 Abs corresponded to IgA. Anti-IC-DSC3 Abs were detected in 44% of patients with pemphigus whose serum anti-desmoglein (DSG) 1-3 Ab profile was inconsistent with their clinical and histological features, according to compensation theory. Anti-IC-DSC3 IgG and IgA Abs induced a dissociation of the keratinocyte monolayer in vitro, which was abolished by preadsorption of these IgG or IgA fractions with recombinant IC-DSC3. In addition, IgG from mice immunized with recombinant IC-DSC3 induced acantholysis in vitro. Finally, in neonatal mice, the passive transfer of an anti-IC-DSC3 mAb in combination with anti-DSG1-3 Abs exacerbated blister formation. CONCLUSIONS: Our findings suggest that anti-IC-DSC3 Abs are pathogenic and explain the discordance seen in some patients with regard to their clinical phenotype and their anti-DSG1-3 Ab profile. Pemphigus is a rare disease where the body’s immune system mistakenly attacks itself. In people with pemphigus, the immune system creates antibodies to two proteins: desmoglein 1 (DSG1) and desmoglein 3 (DSG3). DSG1 and DSG3 help cells in the skin and mucosa (soft tissue that lines some organs) stick together. The antibodies attack DSG1 and DSG3, causing skin cells to separate, leading to painful blisters. Other antibodies that do not target DSG1 and DSG3 may be involved in the disease. One of these other proteins that may be targeted is desmocollin 3 (DSC3). DSC3 is another protein that works with DSG to help skin cells stick together. Antibodies directed against some parts of the DSC3 protein have been found in some types of pemphigus. We developed a new test called the ‘ALBIA’ to look for the presence of antibodies to DSC3 in 146 people with pemphigus. We found that antibodies targeting DSC3 were present in 21% of patients. In the lab, we showed that antibodies targeting a specific part of DSC3 in people with pemphigus could cause damage. We also confirmed their harmful effects in more lab tests and in experiments with mice. Overall, our study shows how the new ALBIA test can be used to detect antibodies that target DSC3 in people with pemphigus. The findings suggest that antibodies directed against a certain part of DSC3 might play a role in causing the disease.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Maho-Vaillant M, Lemieux A, Arnoult C, et al. Prevalence and pathogenic activity of anti-desmocollin-3 antibodies in patients with pemphigus vulgaris and pemphigus foliaceus. Br J Dermatol. 2025. PMID: 39989391. doi:10.1093/bjd/ljaf021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。